Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 176

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

KEYNOTE-585: Phase III Study of Perioperative Chemotherapy with or Without Pembrolizumab for Gastric Cancer

Open access
Bang, Yung-Jue, Van Cutsem, Eric, Fuchs, Charles S, Ohtsu, Atsushi, Tabernero, Josep, Ilson, David H, Hyung, Woo Jin, Strong, Vivian E, Goetze, Thorsten Oliver, Yoshikawa, Takaki, Tang, Laura H, Hwang, Peggy May Tan, Webb, Nancy, Adelberg, David, Shitara, Kohei · 2019 · Future Oncology

Abstract

BACKGROUND: Surgical resection is the only curative treatment option for gastric cancer. Despite widespread adoption of multimodality perioperative treatment strategies, 5-year overall survival rates remain low. In patients with advanced gastric or gastroesophageal junction adenocarcinoma, pembrolizumab has demonstrated promising efficacy and manageable safety as monotherapy in previously treated patients and as first-line therapy in combination with cisplatin and 5-fluorouracil. Combining chemotherapy with pembrolizumab in the neoadjuvant/adjuvant setting may benefit patients with locally advanced, resectable disease. AIM: To describe the design and rationale for the global, multicenter, randomized, double-blind, Phase III KEYNOTE-585 study to evaluate the efficacy and safety of pembrolizumab plus chemotherapy compared with placebo plus chemotherapy as neoadjuvant/adjuvant treatment for localized gastric or gastroesophageal junction adenocarcinoma. ClinicalTrials.gov : NCT03221426.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2217/fon-2018-0581

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 176

Metadata

Authors
Bang, Y.-J., Van Cutsem, E., Fuchs, C. S., Ohtsu, A., Tabernero, J., Ilson, D. H., Hyung, W. J., Strong, V. E., Goetze, T. O., Yoshikawa, T., Tang, L. H., Hwang, P. M. T., Webb, N., Adelberg, D., & Shitara, K.
Venue
Future Oncology
Published
2019-02-19
Volume
15
Issue
9
Pages
943-952
ISSN
  • 1479-6694 (ISSN-L)
  • 1744-8301
OpenAlex
W2917253379
Cited by
176
References
3
FWCI
13.67
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: KEYNOTE-585: Phase III Study of Perioperative Chemotherapy with or Without Pembrolizumab for Gastric Cancer. https://app.cochat.ai/papers/10.2217/fon-2018-0581
The paper
Bang, Y.-J., Van Cutsem, E., Fuchs, C. S., Ohtsu, A., Tabernero, J., Ilson, D. H., Hyung, W. J., Strong, V. E., Goetze, T. O., Yoshikawa, T., Tang, L. H., Hwang, P. M. T., Webb, N., Adelberg, D., & Shitara, K. (2019). KEYNOTE-585: Phase III Study of Perioperative Chemotherapy with or Without Pembrolizumab for Gastric Cancer. Future Oncology. https://doi.org/10.2217/fon-2018-0581

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.